Bringing Next Generation Flow (NGF) Cytometry to Japan

On Saturday and Sunday, the IMF was honored to chair a workshop in Tokyo, Japan, which introduced Next Generation Flow Cytometry to more than 160 researchers and technicians eager to learn about this super-sensitive automated new myeloma measuring method.

Trial Results Show Impressive Benefit of Carfilzomib (Kyprolis®) versus Bortezomib (Velcade®) in Relapsed Myeloma

This week’s news of interim results from the ENDEAVOR trial, a head-to-head comparison of “real world” schedules of Kyprolis versus Velcade, reveals an impressive benefit of carfilzomib over bortezomib in relapsed myeloma. Indeed, the 929-patient phase III trial showed a progression-free survival (PFS) of 18.7 months for Kyprolis versus 9.4 months for Velcade—basically a doubling of PFS or remission duration.

FDA Reverses ODAC Vote and Approves Panobinostat (Farydak®) for Relapsed Myeloma

In a surprise move this week, the US Food and Drug Administration (FDA) approved Farydak®, despite the 5-2 vote by the FDA’s Oncologic Drugs Advisory Committee (ODAC) recommending against approval in November 2014. The approval is obviously good news for the myeloma community.

Revlimid Receives Frontline Approval in the US

In a highly anticipated decision announced this week, the US Food and Drug Administration (FDA) approved the use of Revlimid

Is Measles a Problem for Myeloma patients?

Cases of measles have been very much in the news: 121 cases (as of today) reported in the US this year. To assess how much myeloma patients might need to be concerned or not, it is helpful to put this number of cases in perspective.

Pages